Sign In

Rahul Aras

President & CEO at Iterion Therapeutics

Rahul Aras is a highly motivated executive with over 15 years of experience in the pharma/biotech industry, focusing on advancing early-stage technologies and creating value.

He has a proven track record in financing early-stage companies through various funding sources, including angels, venture capital, and non-dilutive funding.

Rahul possesses extensive international experience in licensing, partnerships, and deal structures, with expertise in all aspects of business development such as deal sourcing, financial models, negotiations, and strategic alliance management.

His technical proficiency extends to working with the FDA to progress innovative biologics through clinical trials, covering product development from discovery to regulatory and clinical operations.

With a broad investment network encompassing venture capital, investment banking, and institutional investors, Rahul is well-connected in the biotechnology and investment sectors.

His educational background includes a Ph.D. in Biomedical Research from NYU School of Medicine and a B.S. in Biology and Child Development from Tufts University.

Throughout his career, Rahul Aras has held various key positions in notable organizations such as President & CEO at Iterion Therapeutics, Business Development Consultant at Harrington Discovery Institute, and Entrepreneur in Residence at Cleveland Clinic Ventures.

He has also contributed his expertise as an advisor and co-founder in several biotech ventures including SironRX Therapeutics and Juventas Therapeutics, Inc.

Rahul's professional journey includes roles at respected institutions like Cleveland Clinic, Cold Spring Harbor Laboratory, and Massachusetts General Hospital, showcasing his diverse experience and contributions to the life sciences field.

Highlights

Feb 20 · linkedin

Iterion Therapeutics is excited have started enrolling our Phase 1b/2a clinical study for tegavivint in patients with adavanced hepatocelluar carcinoma. Its a devastating disease with few therapeutic options and we hope to make a difference in the lives of these patients. To learn more please go to: https://lnkd.in/gTKwsVw5 #cancerresearch #oncologytrials #livercancer #drugdevelopment

May 16 · linkedin

Iterion Therapeutics is honored to be collaborating with Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute on a Phase 1 clinical trial for tegavivint in patients with Diffuse Large B-cell Lymphomas (DLBCL). We're very grateful to National Cancer Institute (NCI) for providing the funding to perform this important study.

#cancerresearch #lymphoma #oncologytrials

Rahul Aras
Add to my network

Location

Sugar Land, Texas, United States